CA2093165A1 - Formulated medicines and processed foods to potentiate host defense activity, and methods for treatment of infectious diseases - Google Patents

Formulated medicines and processed foods to potentiate host defense activity, and methods for treatment of infectious diseases

Info

Publication number: CA2093165A1
Authority: CA; Canada
Prior art keywords: protein; present; composition according; opportunistic; lactoferrin
Prior art date: 1992-04-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002093165A

Other languages

English (en)

French (fr)

Inventor

Kunio Ando

Jun-Ichi Kishimoto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immuno Japan Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-02

Filing date

1993-04-01

Publication date

1993-10-03

1993-04-01 Application filed by Individual filed Critical Individual

1993-10-03 Publication of CA2093165A1 publication Critical patent/CA2093165A1/en

Status Abandoned legal-status Critical Current

Links

208000035473 Communicable disease Diseases 0.000 title claims abstract 3
238000000034 method Methods 0.000 title claims description 13
230000003389 potentiating effect Effects 0.000 title claims description 4
230000000694 effects Effects 0.000 title description 11
239000003814 drug Substances 0.000 title description 3
229940079593 drug Drugs 0.000 title description 2
235000021067 refined food Nutrition 0.000 title description 2
230000007123 defense Effects 0.000 title 1
102000010445 Lactoferrin Human genes 0.000 claims abstract description 23
108010063045 Lactoferrin Proteins 0.000 claims abstract description 23
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 23
229940078795 lactoferrin Drugs 0.000 claims abstract description 23
235000021242 lactoferrin Nutrition 0.000 claims abstract description 23
108090000623 proteins and genes Proteins 0.000 claims abstract description 21
235000018102 proteins Nutrition 0.000 claims abstract description 20
102000004169 proteins and genes Human genes 0.000 claims abstract description 20
241000124008 Mammalia Species 0.000 claims abstract description 12
230000003385 bacteriostatic effect Effects 0.000 claims abstract 5
239000000203 mixture Substances 0.000 claims description 17
235000013305 food Nutrition 0.000 claims description 11
230000003115 biocidal effect Effects 0.000 claims description 8
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 8
235000013336 milk Nutrition 0.000 claims description 8
239000008267 milk Substances 0.000 claims description 8
210000004080 milk Anatomy 0.000 claims description 8
229960000723 ampicillin Drugs 0.000 claims description 6
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 6
229940106164 cephalexin Drugs 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
102000004338 Transferrin Human genes 0.000 claims description 5
108090000901 Transferrin Proteins 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
239000012581 transferrin Substances 0.000 claims description 5
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 4
229960005361 cefaclor Drugs 0.000 claims description 4
241000271566 Aves Species 0.000 claims description 3
230000037396 body weight Effects 0.000 claims description 3
229960002129 cefixime Drugs 0.000 claims description 3
OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims description 3
-1 cephroxazine Chemical compound 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
108010010803 Gelatin Proteins 0.000 claims description 2
239000008273 gelatin Substances 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
229910052742 iron Inorganic materials 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 5
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 4
239000004098 Tetracycline Substances 0.000 claims 3
229960005091 chloramphenicol Drugs 0.000 claims 3
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 3
244000005700 microbiome Species 0.000 claims 3
229960002180 tetracycline Drugs 0.000 claims 3
229930101283 tetracycline Natural products 0.000 claims 3
235000019364 tetracycline Nutrition 0.000 claims 3
150000003522 tetracyclines Chemical class 0.000 claims 3
239000003937 drug carrier Substances 0.000 claims 2
229960003276 erythromycin Drugs 0.000 claims 2
210000000987 immune system Anatomy 0.000 claims 2
241000459479 Capsula Species 0.000 claims 1
108010026206 Conalbumin Proteins 0.000 claims 1
208000001388 Opportunistic Infections Diseases 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
229920006395 saturated elastomer Polymers 0.000 claims 1
208000015181 infectious disease Diseases 0.000 abstract description 4
244000039328 opportunistic pathogen Species 0.000 abstract description 3
230000007246 mechanism Effects 0.000 abstract description 2
230000001404 mediated effect Effects 0.000 abstract description 2
239000004599 antimicrobial Substances 0.000 abstract 1
244000000010 microbial pathogen Species 0.000 abstract 1
230000000242 pagocytic effect Effects 0.000 abstract 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 25
150000002500 ions Chemical class 0.000 description 16
241000699670 Mus sp. Species 0.000 description 11
238000002512 chemotherapy Methods 0.000 description 8
210000000440 neutrophil Anatomy 0.000 description 6
210000004027 cell Anatomy 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
108010013381 Porins Proteins 0.000 description 4
102000007739 porin activity proteins Human genes 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000588769 Proteus <enterobacteria> Species 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
230000001010 compromised effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
244000052769 pathogen Species 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241001478240 Coccus Species 0.000 description 1
241001137251 Corvidae Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
244000182625 Dictamnus albus Species 0.000 description 1
101100130497 Drosophila melanogaster Mical gene Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241001543257 Escherichia coli O11 Species 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
101000973623 Homo sapiens Neuronal growth regulator 1 Proteins 0.000 description 1
101000657326 Homo sapiens Protein TANC2 Proteins 0.000 description 1
OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001024304 Mino Species 0.000 description 1
241000588772 Morganella morganii Species 0.000 description 1
101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102100022223 Neuronal growth regulator 1 Human genes 0.000 description 1
101100409308 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) adv-1 gene Proteins 0.000 description 1
241000700124 Octodon degus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000644027 Perideridia lemmonii Species 0.000 description 1
241000312117 Phago Species 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
102100034784 Protein TANC2 Human genes 0.000 description 1
244000292604 Salvia columbariae Species 0.000 description 1
235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
235000001498 Salvia hispanica Nutrition 0.000 description 1
241000896524 Sarcophaga par Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241001467018 Typhis Species 0.000 description 1
101710097943 Viral-enhancing factor Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000000719 anti-leukaemic effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000036765 blood level Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
RIWWMGQFMUUYIY-ALLHVENQSA-M cefpiramide sodium Chemical compound [Na+].C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 RIWWMGQFMUUYIY-ALLHVENQSA-M 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
235000014167 chia Nutrition 0.000 description 1
229940003372 compro Drugs 0.000 description 1
230000002153 concerted effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
235000014103 egg white Nutrition 0.000 description 1
210000000969 egg white Anatomy 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940088592 immunologic factor Drugs 0.000 description 1
230000008676 import Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
QBQQKHZEHKZMJF-NXUSYKNTSA-N mioe Chemical compound C=1([C@@H]2OC(=O)C[C@@H]3[C@@]2(C)CC[C@H]2C3=C[C@@H]3[C@@H](OC(=O)C(C)C)C(C)(C)[C@@H]([C@@]2(C)C3=O)CC(=O)OC)C=COC=1 QBQQKHZEHKZMJF-NXUSYKNTSA-N 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000015108 pies Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
230000004044 response Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000002226 simultaneous effect Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229950008418 talipexole Drugs 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

CA002093165A 1992-04-02 1993-04-01 Formulated medicines and processed foods to potentiate host defense activity, and methods for treatment of infectious diseases Abandoned CA2093165A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP152620/92		1992-04-02
JP4152620A JPH06145068A (ja)	1992-04-02	1992-04-02	生体防御能賦活剤・感染症治療剤・生体防御能賦活性食品

Publications (1)

Publication Number	Publication Date
CA2093165A1 true CA2093165A1 (en)	1993-10-03

Family

ID=15544364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002093165A Abandoned CA2093165A1 (en)	1992-04-02	1993-04-01	Formulated medicines and processed foods to potentiate host defense activity, and methods for treatment of infectious diseases

Country Status (3)

Country	Link
EP (3)	EP1013282A3 (2)
JP (1)	JPH06145068A (2)
CA (1)	CA2093165A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0696455A1 (en)	1994-08-11	1996-02-14	Cellena (Cell Engineering) A.G.	Transferrin compositions to alleviate the side effects of cytotoxic drugs
JPH08217693A (ja) *	1995-02-17	1996-08-27	Yoshihisa Naito	新規医薬組成物
US5985275A (en) *	1995-04-12	1999-11-16	New York Blood Center	β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US5834424A (en) *	1995-07-12	1998-11-10	Gambit International Limited	Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
US5952009A (en) *	1996-03-20	1999-09-14	New York Blood Center	Methods for preventing the transmission of or treating patients infected with herpesvirus
WO1997047308A1 (en) *	1996-06-11	1997-12-18	Cellena Ag	Eutrophic drug compositions based on transferrin glycans
JP2001504447A (ja) *	1996-08-12	2001-04-03	エイプラスサイエンスインベストアーベー	ラクトフェリンおよび／またはラクトフェリシンでの、感染、炎症および／または腫瘍の処置および予防
US6172040B1 (en) *	1999-05-28	2001-01-09	A. Satyanarayan Naidu	Immobilized lactoferrin antimicrobial agents and the use thereof
JP4679687B2 (ja) *	2000-02-16	2011-04-27	雪印乳業株式会社	肝機能改善剤
WO2003088914A2 (en) *	2002-04-18	2003-10-30	The University Of Iowa Research Foundation	Methods of inhibiting and treating bacterial biofilms by metal chelators
CA2508912A1 (en) *	2002-12-06	2004-06-24	Agennix Incorporated	Oral lactoferrin in the treatment of sepsis
GB0229658D0 (en) *	2002-12-20	2003-01-22	Cleeve Richard J	Bird feed
WO2005085287A1 (en)	2004-03-03	2005-09-15	En-N-Tech, Inc.	Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
US20070191264A1 (en) *	2005-05-05	2007-08-16	Bristol-Myers Squibb Company, A Delaware Corporation	Methods for inhibiting the growth of bacteria
ITMI20052351A1 (it) *	2005-12-09	2007-06-10	Microbo Srl	Nuovo uso farmaceutico delle transferrine e composizioni farmaceutiche derivate
ITLU20070009A1 (it) *	2007-05-21	2008-11-22	Kedrion Spa	Uso di transferrina per la preparazione di composizioni farmaceutiche utili per il trattamento di infezioni batteriche come coadiuvanti nella terapia antibiotica.
US20130310307A1 (en) *	2012-04-26	2013-11-21	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Methods and compositions for treatment of multidrug-resistant bacterial and fungal infections
WO2020130803A1 (en) *	2018-12-21	2020-06-25	N.V. Nutricia	Protein compositions with high isoelectric proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4405606A (en) *	1981-05-04	1983-09-20	Evreka, Inc.	Method for arresting fulminating infection
JPH03181421A (ja) *	1989-12-08	1991-08-07	Chugai Pharmaceut Co Ltd	ベータラクタム系抗生物質の作用増強剤並びに感染症予防及び治療用の医薬組成物
US5198419A (en) *	1989-12-08	1993-03-30	Immuno Japan Inc.	Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria

1992
- 1992-04-02 JP JP4152620A patent/JPH06145068A/ja active Pending
1993
- 1993-04-01 CA CA002093165A patent/CA2093165A1/en not_active Abandoned
- 1993-04-01 EP EP00200142A patent/EP1013282A3/en not_active Withdrawn
- 1993-04-01 EP EP93302568A patent/EP0568200A2/en not_active Withdrawn
- 1993-04-01 EP EP00200143A patent/EP1013283A3/en not_active Withdrawn

Also Published As

Publication number	Publication date
JPH06145068A (ja)	1994-05-24
EP1013282A2 (en)	2000-06-28
EP0568200A3 (2)	1994-01-12
EP1013283A3 (en)	2002-08-07
EP0568200A2 (en)	1993-11-03
EP1013282A3 (en)	2002-08-07
EP1013283A2 (en)	2000-06-28

Legal Events

Date	Code	Title	Description
1997-04-01	FZDE	Dead

Publication	Publication Date	Title
Tsai et al.	2000	Enhancing effect of patented whey protein isolate (Immunocal) on cytotoxicity of an anticancer drug
Matsumori et al.	1987	Prevention of viral myocarditis with recombinant human leukocyte interferon α A/D in a murine model
JP4592127B2 (ja)	2010-12-01	骨吸収抑制剤
EP1200463B1 (en)	2015-11-11	Antimicrobial histone h1 compositions and methods of use thereof
EP0568200A2 (en)	1993-11-03	Pharmaceutical and foodstuff compositions containing transferrius and antibacteral agents for potentiating host defense activity and the treatment of infections
EP1006124B1 (en)	2006-09-13	Immunomodulatory materials from Calliphora vicina larvae, their preparation and use
JP2832517B2 (ja)	1998-12-09	大腸菌付着阻止剤
RU2146526C1 (ru)	2000-03-20	Лечебно-профилактический препарат в твердой и мягкой формах и способ профилактики и лечения дисбактериоза и урогенитальных инфекций
JP2002519332A (ja)	2002-07-02	微生物によって引き起こされる表面感染症の治療または予防に使用するための医薬調製物
KR20020053064A (ko)	2002-07-04	질병 치료를 위한 저용량의 ｉｆｎ-감마
AU709620B2 (en)	1999-09-02	New applications of lysozyme dimer
US9446128B2 (en)	2016-09-20	Composition comprising egg white combined chalcanthite for preventing or treating cancer
US5543392A (en)	1996-08-06	Digestive tract cell activating agent of EGF and lactoferrin
US6183742B1 (en)	2001-02-06	Applications of lysozyme dimer
Kamagata-Kiyoura et al.	2004	Protective effects of human saliva on experimental murine oral candidiasis
US20160213730A1 (en)	2016-07-28	Identification of natural plant extracts harboring anti-hepatitis c virus ns5b polymerase activity
US20050201952A1 (en)	2005-09-15	Treatment and prevention of viral hepatitis infections
WO2012033261A1 (ko)	2012-03-15	제니핀 또는 이의 유도체를 포함하는 패혈증 예방 또는 치료용 약학적 조성물
KR100509249B1 (ko)	2005-08-22	코코아 성분을 함유하는 의약품, 음식물 및 사료
US6270756B1 (en)	2001-08-07	Weight loss induced by alpha interferon and gamma interferon
CN116478243B (zh)	2024-01-26	血吸虫来源肽在防治代谢性疾病中的应用
Meadows et al.	1988	Response of natural killer cells from dietary tyrosine-and phenylalanine-restricted mice to biological response modifiers
AU2003273444B2 (en)	2010-05-20	Use of Ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass
KR20010101065A (ko)	2001-11-14	표고버섯 균사체 추출물 유래의 ｌａｋ 활성증강물질 및이를 함유하는 ｌａｋ 활성증강용 제제
RO128485A0 (ro)	2013-06-28	Compoziţie cu biodisponibilitate crescută a embrio-peptidelor administrate oral şi procedeu de obţinere